Genmab A/S (OTCMKTS:GNMSF) Shares Gap Down – Time to Sell?

Genmab A/S (OTCMKTS:GNMSF)’s share price gapped down before the market opened on Monday . The stock had previously closed at $290.00, but opened at $260.00. Genmab A/S shares last traded at $260.00, with a volume of 29 shares trading hands.

Genmab A/S Trading Down 3.8%

The company has a quick ratio of 2.01, a current ratio of 2.02 and a debt-to-equity ratio of 0.86. The firm has a 50 day moving average of $312.42 and a 200 day moving average of $306.16. The firm has a market cap of $16.31 billion, a PE ratio of 17.11 and a beta of 0.92.

Genmab A/S (OTCMKTS:GNMSF) last released its earnings results on Tuesday, February 17th. The company reported $0.55 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.10 by ($2.55). The firm had revenue of $1.06 billion during the quarter, compared to analysts’ expectations of $1.05 billion. Genmab A/S had a return on equity of 17.35% and a net margin of 25.89%.

About Genmab A/S

Genmab A/S is a biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer and other serious diseases. The company’s core expertise lies in its proprietary antibody platforms, including DuoBody®, HexaBody® and HexElect®, which enable the design and engineering of novel bispecific and enhanced-effector antibodies. Genmab’s science-driven approach integrates advanced protein engineering with insights into tumor biology to generate candidates that can engage the immune system, disrupt disease pathways and offer potential safety and efficacy advantages over conventional therapies.

Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab has grown into a global organization with research and development facilities in Utrecht, the Netherlands, and commercial and clinical support offices in the United States.